Predictive factors for recurrence after thyroid lobectomy for unilateral nontoxic goiter in an endemic area: Results of a multivariate analysis

被引:40
作者
Bellantone, R
Lombardi, CP
Boscherini, M
Raffaelli, M
Tondolo, V
Alesina, PF
Corsello, SM
Fintini, D
Bossola, M
机构
[1] Catholic Univ, Div Endocrine Surg, I-00168 Rome, Italy
[2] Catholic Univ, Div Endocrinol, I-00168 Rome, Italy
关键词
D O I
10.1016/j.surg.2004.06.054
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background. The aim of the study was to identify the factors that are Predictive of recurrence after thyroid lobectomy for unilateral non-toxic thyroid goiter in an endemic region through a multivariate analysis. Methods. Two hundred sixty-eight consecutive patients who underwent thyroid lobectomy and who were evaluated by the same endocrinologist were included. Univariate and multivariate analysis analyzed the relationship between sex, age, preoperative thyroid-stimulaling hormone, duration of disease, duration Of levothyroxine (LT4) preoperative therapy, cytologic results, histologic results, resected thyroid weight, numbers and diameters of thyroid nodules, morphologic alterations of the remnant lobe, follow-up length, postoperative LT4 therapy, ultrasonographic evidence of recurrence, and reoperation. Results The incidence of recurrance was 33.9% (91/268 patients) after a mean follow-up time of 79.9 months (range, 12-251 months), female sex (P = .016), multiple nodules (P = .017), and lack of postoperative LT4 therapy (P = .0009) were predictive factors of recurrence. Reoperation was Performed in 20 patients (7.4%); factors that were predictive of reoperation were the presence of multiple nodules (P = .008), resected thyroid weight (P = .00006), and lack of postoperative hormonal therapy (P = .0005). Conclusions. Thyroid lobectomy for unilateral non-toxic goiter, when combined with suppressive or substitutive thyroxin therapy, resulted in a low rate Of recurrence and reoperation in an endemic area.
引用
收藏
页码:1247 / 1250
页数:4
相关论文
共 21 条
  • [1] ANDERSON PE, 1990, SURG GYNECOL OBSTET, V171, P309
  • [2] THE LONG-TERM OUTCOME OF THYROIDECTOMY FOR SPORADIC NON-TOXIC GOITER
    BERGHOUT, A
    WIERSINGA, WM
    DREXHAGE, HA
    VANTROTSENBURG, P
    SMITS, NJ
    VANDERGAAG, RD
    TOUBER, JL
    [J]. CLINICAL ENDOCRINOLOGY, 1989, 31 (02) : 193 - 199
  • [3] BERGLUND J, 1990, ACTA CHIR SCAND, V156, P433
  • [4] BISTRUP C, 1994, CLIN ENDOCRINOL, V40, P323
  • [5] Iodized salt improves the effectiveness of L-thyroxine therapy after surgery for nontoxic goitre: a prospective and randomized study
    Carella, C
    Mazziotti, G
    Rotondi, M
    Del Buono, A
    Zito, G
    Sorvillo, F
    Manganella, G
    Santini, L
    Amato, G
    [J]. CLINICAL ENDOCRINOLOGY, 2002, 57 (04) : 507 - 513
  • [6] CHANGES IN BONE MASS DURING PROLONGED SUBCLINICAL HYPERTHYROIDISM DUE TO L-THYROXINE TREATMENT - A METAANALYSIS
    FABER, J
    GALLOE, AM
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1994, 130 (04) : 350 - 356
  • [7] Iodide or L-thyroxine to prevent recurrent goiter in an iodine-deficient area: Prospective sonographic study
    Feldkamp, J
    Seppel, T
    Becker, A
    Klisch, A
    Schlaghecke, R
    Goretzki, PE
    Roher, HD
    [J]. WORLD JOURNAL OF SURGERY, 1997, 21 (01) : 10 - 14
  • [8] ENDEMIC GOITER AND ENDEMIC THYROID-DISORDERS
    GAITAN, E
    NELSON, NC
    POOLE, GV
    [J]. WORLD JOURNAL OF SURGERY, 1991, 15 (02) : 205 - 215
  • [9] RECURRENCE OF NONTOXIC GOITER WITH AND WITHOUT POSTOPERATIVE THYROXINE MEDICATION
    GEERDSEN, JP
    FROLUND, L
    [J]. CLINICAL ENDOCRINOLOGY, 1984, 21 (05) : 529 - 533
  • [10] Is routine thyroxine treatment to hinder postoperative recurrence of nontoxic goiter justified?
    Hegedüs, L
    Nygaard, B
    Hansen, JM
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (02) : 756 - 760